{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:42:50Z","timestamp":1760182970367,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.rdc.2011.07.006","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T17:50:47Z","timestamp":1319737847000},"page":"337-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Therapies for Osteoporosis"],"prefix":"10.1016","volume":"37","author":[{"given":"Chad","family":"Deal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2011.07.006_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11914-007-0007-z","article-title":"The biology of osteocytes","volume":"5","author":"Kogianni","year":"2007","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"10.1016\/j.rdc.2011.07.006_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Bonewald","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.rdc.2011.07.006_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1172\/JCI33612","article-title":"Building bone to reverse osteoporosis and repair fractures","volume":"118","author":"Khosla","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.rdc.2011.07.006_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.rdc.2011.07.006_bib5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00198-009-1004-0","article-title":"Of mice and men: divergent risks of teriparatide-induced osteosarcoma","volume":"21","author":"Subbiah","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.rdc.2011.07.006_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.rdc.2011.07.006_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jmg.2005.036673","article-title":"Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment","volume":"43","author":"Del Fattore","year":"2006","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.rdc.2011.07.006_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/138161207780162962","article-title":"Emerging roles of cysteine cathepsins in disease and their potential as drug targets","volume":"13","author":"Vasiljeva","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.rdc.2011.07.006_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/sj.clpt.6100450","article-title":"Cathepsin K inhibitors: a novel target for osteoporosis therapy","volume":"83","author":"Stoch","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rdc.2011.07.006_bib10","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","article-title":"Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency","volume":"273","author":"Gelb","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.rdc.2011.07.006_bib11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bmcl.2007.12.047","article-title":"The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K","volume":"18","author":"Gauthier","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"10.1016\/j.rdc.2011.07.006_bib12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","article-title":"Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density","volume":"25","author":"Bone","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.rdc.2011.07.006_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect","volume":"26","author":"Eisman","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.rdc.2011.07.006_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/jbmr.335","article-title":"Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?","volume":"26","author":"Bauer","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.rdc.2011.07.006_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bone.2006.09.025","article-title":"Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women","volume":"40","author":"Henriksen","year":"2007","journal-title":"Bone"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2011.07.006_bib16","first-page":"S37","article-title":"GLP-2 significantly increases hip BMD in postmenopausal women: a 120-day study","volume":"22","author":"Henriksen","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.rdc.2011.07.006_bib17","first-page":"S474","article-title":"GLP-2 acutely uncouples bone resorption and bone formation in postmenopausal women","volume":"23","author":"Henriksen","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.rdc.2011.07.006_bib18","first-page":"S77","article-title":"Nitroglycerine improves bone mineral density, bone geometry, and bone strength: results from a two-year randomized controlled trial","volume":"25","author":"Jamal","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.rdc.2011.07.006_bib19","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1359\/JBMR.040716","article-title":"Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial","volume":"19","author":"Jamal","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.rdc.2011.07.006_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group","volume":"339","author":"Cummings","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2011.07.006_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1749-6632.2009.05230.x","article-title":"Nitric oxide and bone","volume":"1192","author":"Wimalawansa","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.rdc.2011.07.006_bib22","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1517\/14656566.9.11.1935","article-title":"Nitric oxide: new evidence for novel therapeutic indications","volume":"9","author":"Wimalawansa","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.rdc.2011.07.006_bib23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1196\/annals.1402.066","article-title":"Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans","volume":"1117","author":"Wimalawansa","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.rdc.2011.07.006_bib24","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1210\/jc.2009-2342","article-title":"Use of organic nitrates and the risk of hip fracture: a population-based case-control study","volume":"95","author":"Pouwels","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.rdc.2011.07.006_bib25","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1210\/jc.2008-2225","article-title":"Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss","volume":"94","author":"Wimalawansa","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.rdc.2011.07.006_bib26","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jama.2011.176","article-title":"Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial","volume":"305","author":"Jamal","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2011.07.006_bib27","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2011.07.006_bib28","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2011.07.006_bib29","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1210\/en.2006-1372","article-title":"In\u00a0vivo analysis of Wnt signaling in bone","volume":"148","author":"Glass","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.rdc.2011.07.006_bib30","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton","volume":"148","author":"Baron","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.rdc.2011.07.006_bib31","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1210\/jc.2005-1235","article-title":"Bone mineral density in sclerosteosis; affected individuals and gene carriers","volume":"90","author":"Gardner","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2011.07.006_bib32","first-page":"S37","article-title":"Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women","volume":"22","author":"Padhi","year":"2007","journal-title":"J\u00a0Bone Miner Metab"},{"key":"10.1016\/j.rdc.2011.07.006_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1359\/jbmr.081235","article-title":"Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone","volume":"24","author":"Williams","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.rdc.2011.07.006_bib34","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nm.2098","article-title":"Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis","volume":"16","author":"Yadav","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.rdc.2011.07.006_bib35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archinte.167.2.188","article-title":"Effect of selective serotonin reuptake inhibitors on the risk of fracture","volume":"167","author":"Richards","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2011.07.006_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0092-8674(00)81558-5","article-title":"Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass","volume":"100","author":"Ducy","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.rdc.2011.07.006_bib37","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrrheum.2009.231","article-title":"Bone: serotonin, leptin and the central control of bone remodeling","volume":"5","author":"Rosen","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2011.07.006_bib38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMp0810058","article-title":"Serotonin rising\u2013the bone, brain, bowel connection","volume":"360","author":"Rosen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2011.07.006_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-4020-6191-2_6","article-title":"The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics","volume":"45","author":"Brown","year":"2007","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.rdc.2011.07.006_bib40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/dbio.1996.0104","article-title":"Haploinsufficiency of parathyroid hormone-related peptide results in abnormal postnatal bone development","volume":"175","author":"Amizuka","year":"1996","journal-title":"Dev Biol"},{"key":"10.1016\/j.rdc.2011.07.006_bib41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/jc.2002-021122","article-title":"Short-term parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis","volume":"88","author":"Horwitz","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.rdc.2011.07.006_bib42","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1210\/jc.2009-0233","article-title":"Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose","volume":"95","author":"Horwitz","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X11000330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X11000330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:09:43Z","timestamp":1760180983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X11000330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0889857X11000330"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2011.07.006","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Therapies for Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2011.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}